- Home
- NMRK vs WGS Comparison
NMRK vs WGS Comparison
Compare NMRK & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- WGS
- Stock Information
- Founded
- NMRK 1929
- WGS 2017
- Country
- NMRK United States
- WGS United States
- Employees
- NMRK N/A
- WGS N/A
- Industry
- NMRK Real Estate
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- NMRK Finance
- WGS Technology
- Exchange
- NMRK Nasdaq
- WGS Nasdaq
- Market Cap
- NMRK 2.3B
- WGS 2.0B
- IPO Year
- NMRK 2017
- WGS N/A
- Fundamental
- Price
- NMRK $14.16
- WGS $95.83
- Analyst Decision
- NMRK Buy
- WGS Strong Buy
- Analyst Count
- NMRK 4
- WGS 5
- Target Price
- NMRK $17.50
- WGS $82.60
- AVG Volume (30 Days)
- NMRK 902.9K
- WGS 1.4M
- Earning Date
- NMRK 02-14-2025
- WGS 02-18-2025
- Dividend Yield
- NMRK 0.84%
- WGS N/A
- EPS Growth
- NMRK 43.59
- WGS N/A
- EPS
- NMRK 0.34
- WGS N/A
- Revenue
- NMRK $2,754,081,000.00
- WGS $305,450,000.00
- Revenue This Year
- NMRK $11.07
- WGS $44.70
- Revenue Next Year
- NMRK $8.43
- WGS $16.73
- P/E Ratio
- NMRK $41.61
- WGS N/A
- Revenue Growth
- NMRK 11.48
- WGS 50.79
- 52 Week Low
- NMRK $9.44
- WGS $7.16
- 52 Week High
- NMRK $16.10
- WGS $115.60
- Technical
- Relative Strength Index (RSI)
- NMRK 54.16
- WGS 59.30
- Support Level
- NMRK $14.06
- WGS $65.10
- Resistance Level
- NMRK $14.90
- WGS $115.60
- Average True Range (ATR)
- NMRK 0.49
- WGS 9.03
- MACD
- NMRK 0.04
- WGS 3.96
- Stochastic Oscillator
- NMRK 39.15
- WGS 65.30
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.